Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04023019 · ClinicalTrials.gov registry record
Treatment of Hemophilia A Patients With FVIII Inhibitors
A clinical trial of Hemophilia A, sponsored by Emory University.
- Recruiting
- Registry status
- 120
- Enrollment target
- 2
- Study locations
NCT04023019 is a study of Hemophilia A that is actively recruiting participants, run by Emory University. The registered enrollment target is 120 participants, above the 89-participant average among 42 other Hemophilia A trials with a reported enrollment target (35% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT04023019, a study of Hemophilia A, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a non-interventional, multicenter, observational, international study in male persons with haemophilia A who have developed inhibitors to any replacement coagulation factor VIII (FVIII) product. The purpose of the study is to capture different approaches in the management of persons with haemophilia A and FVIII inhibitors, document current immune tolerance induction approaches, and evaluate the efficacy and safety of immune tolerance induction, including the combination of FVIII and emicizumab. Patients will be assigned to 1 of 3 groups based on the treatments they receive, and may switch to another group if their treatment is changed. Participants will be followed after a maximum observational period of 5 years.
Conditions Studied
Interventions
- BIOLOGICAL Emicizumab
- BIOLOGICAL Nuwiq
- BIOLOGICAL Octanate
- BIOLOGICAL Wilate
- BIOLOGICAL Recombinant factor VIIa (rFVIIa)
Study Locations (2)
Georgia
- Arthur M. Blank Hospital - Atlanta
Other
- HZRM Hämophilie-Zentrum Rhein Main - Mörfelden-Walldorf
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-03-17 |
| Est. Completion | 2029-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04023019
The ClinicalTrials.gov registry entry for NCT04023019 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 89-participant average among 42 other Hemophilia A trials with a reported enrollment target (35% higher). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 5 interventions - of which Emicizumab is the first listed.
NCT04023019 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Other.
Frequently Asked Questions
What is clinical trial NCT04023019 about?
NCT04023019 is a clinical study titled "Treatment of Hemophilia A Patients With FVIII Inhibitors". This is a non-interventional, multicenter, observational, international study in male persons with haemophilia A who have developed inhibitors to any replacement coagulation factor VIII (FVIII) product. The purpose of the study is to capture different approaches in the management of persons with hae...
What is the current status of trial NCT04023019?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2020-03-17. Estimated completion is 2029-06.
What conditions does trial NCT04023019 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT04023019?
The interventions under investigation include: Emicizumab (BIOLOGICAL), Nuwiq (BIOLOGICAL), Octanate (BIOLOGICAL), Wilate (BIOLOGICAL), Recombinant factor VIIa (rFVIIa) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04023019?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04023019 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RECRUITING · Phase 4
-
Hemophilia A Research Program
RECRUITING
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.